Tubulointerstitial disease in diabetic nephropathy

International Journal of Nephrology and Renovascular Disease

Volumn 7, Issue , 2014, Pages 107-115

  Tonolo, Giancarlo ^a   Cherchi, Sara ^a  

^a San Giovanni di Dio Hospital   (Italy)

Author keywords

Diabetes; ESRD; Ox LDL; TGF 1

Indexed keywords

ANGIOTENSINOGEN; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; BLOOD GLUCOSE MONITORING; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HORMONE URINE LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INTERSTITIUM; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE;

EID: 84897008461     PISSN: None     EISSN: 11787058     Source Type: Book Series    
DOI: 10.2147/IJNRD.S37883     Document Type: Review

References (101)

1. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24): 2532-2539.
2. Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood). 2008;233(1): 4-11.
3. Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol. 2011;1(3):1175-1232.
4. Mauer M. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994;45(2):612-622.
5. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed). 1988;296(6616):156-160.
6. Viberti GC, Hill RD, Jarret RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1(8287):1430-1432.
7. Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh). 1982;100(4):550-552.
8. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1986;331(2):89-93.
9. Karamanos B, Fuller JH, Stevens LK. Short duration of IDDM with microangiopathy vs long duration without risk: determinants and protective factors. Diabetologia. 1996;39(Suppl 1):A26.
10. Retnakaran R, Cull CA, Thome KI, et al. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-1839.
11. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is non albuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care. 2006;29(7):1560-1566.
12. Rossi MC, Nicolucci A, Pellegrini F, et al. Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: the DEMAND Study. Nutr Metab Cardiovasc Dis. 2010;20(2):110-116.
13. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in type 2 NIDDM patients with microalbuminuria. Diabetologia.1996;39(12):1569-1576.
14. Fioretto P, Stehouwer CD, Mauer M, et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia. 1998;41(2):233-236.
15. Nosadini R, Velussi M, Brocco E, et al. Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms. Diabetes. 2005;54(1):228-233.
16. Nosadini R, Velussi M, Brocco E, et al. Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria. Diabetes. 2006;55(1):234-239.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
18. de Boer IH, Rue TC, Cleary PA, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011;171(5):412-420.
19. Faronato PP, Maioli M, Tonolo G, et al. Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group. Diabetologia. 1997;40(7):816-823.
20. Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH. Incidence of nephropathy in type 2 diabetes mellitus in the Pima Indians. Kidney Int. 1989;35:681-687.
21. Nelson RG, Pettitt DJ, Baird HR. Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1993;33(10):998-1001.
22. Nelson RG, Pettitt DJ, de Courten MP, et al. Parental hypertension and proteinuria in Pima Indians with NIDDM. Diabetologia. 1996;39(4):433-438.
23. Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis. 2006;47(2):223-232.
24. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27(2):195-207.
25. Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Kark RM. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959;38:321-367.
26. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia. 2008;51(8):1347-1355.
27. Bohle A, Wehrmann M, Bogenschutz O, et al. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract. 1991;187(2-3): 251-259.
28. Marcussen N. A tubular glomeruli and the structural basis for chronic renal failure. Lab Invest. 1992;66:265-284.
29. Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008;4(4):216-226.
30. D'Amico G, Ferrario F, Rastaldi MP. Tubulointerstitial damage in glomerular diseases: its role in the progression of renal damage. Am J Kidney Dis. 1995;26(1):124-132.
31. Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-d-glucosaminidase. Kidney Int. 2011;79(4):464-470.
32. Ziyadeh FN, Snipes ER, Watanabe M, et al. High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am J Physiol. 1990;259(4 Pt 2):F704-F714.
33. Zhu Y, Usui HK, Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol. 2007;27(2):153-160.
34. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest. 1994;93(2):536-542.
35. Fraser D, Brunskill N, Ito T, Phillips A. Long-term exposure of proximal tubular epithelial cells to glucose induces transforming growth factor-beta 1 synthesis via an autocrine PDGF loop. Am J Pathol. 2003;163(6):2565-2574.
36. Roksnoer LC, Verdonk K, van den Meiracker AH, et al. Urinary markers of intrarenal renin-angiotensin system activity in vivo. Curr Hypertens Rep. 2013;15(2):81-88.
37. Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci. 2009;338(6):478-480.
38. Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci. 2012;119(4): 314-323.
39. Hong CY, Hughes K, Chia KS, Ng V, Ling SL. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care. 2003;26(2):338-342.
40. Korpinen E, Teppo AM, Hukkanen L, et al. Urinary transforming growth factor-beta1 and alpha1-microglobulin in children and adolescents with type 1 diabetes. Diabetes Care. 2000;23(5):664-668.
41. Terami T, Wada J, Inoue K, et al. Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes. Int J Nephrol Renovasc Dis. 2013;6:233-240.
42. Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881-889.
43. Hata A, Davis BN. Control of microRNA biogenesis by TGFbeta signaling pathway: a novel role of Smads in the nucleus. Cytokine Growth Factor Rev. 2009;20(5-6):517-521.
44. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126-139.
45. Wang Q, Wang Y, Minto AW, et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 2008;22(12):4126-4135.
46. Zhang Z, Peng H, Chen J, et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009;583(12):2009-2014.
47. Fu Y, Zhang Y, Wang Z, et al. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol. 2010;32(6):581-589.
48. Brosius FC, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503-2512.
49. Soler MJ, Riera M, Batlle D. New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy. Exp Diabetes Res. 2012;2012:616313.
50. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis. 2010;20(1):72-77.
51. Meyer C, Gerich JE. Role of the kidney in hyperglycemia in type 2 diabetes. Curr Diab Rep. 2002;2(3):237-241.
52. Woerle HJ, Popa E, Dostou J, et al. Exogenous insulin replacement in type 2 diabetes reverses excessive hepatic glucose release, but not excessive renal glucose release and impaired free fatty acid clearance. Metabolism. 2002;51(11):1494-1500.
53. Wang Z, Jiang T, Li J, Proctor G, McManam JL, Lucia S et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 2005;54(8):2328-2335.
54. Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest. 2009;119(1):136-145.
55. Agarwal A, Balla J, Balla G, et al. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Physiol. 1996;271(4 Pt 2):F814-F823.
56. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004;24(1):46-53.
57. Santini E, Lupi R, Baldi S, et al. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia. 2008;51(11):2117-2225.
58. Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21(2):79-85.
59. Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type II diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997;20(12): 1891-1895.
60. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1): 260-269.
61. Tabatabai NM, Sharma M, Blumenthal SS, Petering DH. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009;83(1):e27-e30.
62. Ziyadeh FN, Snipes ER, Watanabe M, et al. High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am J Physiol. 1990;259(4 Pt 2):F704-F714.
63. Polhill TS, Saad S, Poronnik P, Fulcher GR, Pollock CA. Short-term peaks in glucose promote renal fibrogenesis independently of total glucose exposure. Am J Physiol Renal Physiol. 2004;287(2): F268-F273.
64. Ihm CG, Lee GS, Nast CC, et al. Early increased renal procollagen alpha 1(IV) mRNA levels in streptozotocin induced diabetes. Kidney Int. 1992;41(4):768-777.
65. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5-14.
66. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442.
67. Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm Metab Res. 2009;41(8):585-593.
68. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87(2): 432-438.
69. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008;4(1):39-45.
70. Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol. 2013;182(1):132-141.
71. Glorie LL, Verhulst A, Matheeussen V, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2012;303(5):F681-F688.
72. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res. 2012;36(1):65-84.
73. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. SAVOR-TIMI 53 Steering Committee and Investigators. N Engl J Med. 2013;369(14):1317-1326.
74. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia. 2003;46(6):1153-1160.
75. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens. 2009;18(1):15-20.
76. Nath KA, Croatt AJ, Hostetter TH. Oxygen consumption and oxidant stress in surviving nephrons. Am J Physiol. 1990;258(5 Pt 2): F1354-F1362.
77. Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int. 1997;52(3):637-647.
78. Lin CL, Wang FS, Kuo YR, et al. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int. 2006;69(9):1593-1600.
79. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Cur Opin Nephrol Hypertens. 2001;10(2):219-225.
80. Diamond-Stanic MK, You YH, Sharma K. Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol. 2012;32(3):261-268.
81. Franconi F, Campesi I, Occhioni S, Tonolo G. Sex-gender differences in diabetes vascular complications and treatment. Endocr Metab Immune Disord Drug Targets. 2012;12(2):179-196.
82. Schulb CJ, Konopelska-Bahu T, Dalton RN, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care. 1999;22(3): 495-502.
83. Maric C. Sex, diabetes and the kidney. Am J Physiol Renal Physiol. 2009;296(4):F680-F688.
84. Harjutsalo V, Maric C, Forsblom C, et al. Sex-related differences in the long-term risk of microvascular complication by age at onset of type 1 diabetes. Diabetologia. 2011;54(8):1992-1999.
85. Lin Y, Nakachi K, Ito Y, et al. Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults. Dis Markers. 2009;27(1):23-28.
86. Elliot SJ, Berho M, Korach K, et al. Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57BI/6J mice develop glomerulosclerosis. Kidney Int. 2007;72(4):464-472.
87. Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol. 2005;288(2):F399-F405.
88. Catanuto P, Doublier S, Lupia E, et al. 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Kidney Int. 2009;75(11):1194-1201.
89. Dixon A, Maric C. 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am J Physiol Renal Physiol. 2007;293(5):F1678-F1690.
90. Yanes LL, Sartori-Valinotti JC, Reckelhoff JF. Sex steroids and renal disease: lessons from animal studies. Hypertension. 2008;51(4): 976-981.
91. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85(4):447-452.
92. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613.
93. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477.
94. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-2602.
95. Maric C, Forsblom C, Thorn L, Waden J, Groop PH. Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids. 2010;75(11):772-778.
96. Prabhu A, Xu Q, Manigrasso MB, et al. Expression of aromatase, androgen and estrogen receptors in peripheral target tissues in diabetes. Steroids. 2010;75(11):779-787.
97. Cherney DZ, Sochett EB, Miller JA. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney Int. 2005;68(4):1722-1728.
98. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States. 1988-2000. JAMA. 2003;290(2):199-206.
99. Thoenes M, Neuberger HR, Volpe M, et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum. Hypertens. 2010;24(5):336-344.
100. Freire MB, Ji L, Onuma T, et al. Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension. 1998;31(4):896-899.
101. Pettersson-Fernholm K, Frojdo S, Fagerudd J, et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. Kidney Int. 2006;69(10):1880-1884.